ADIPOQ and metabolic dysfunction-associated steatotic liver disease: All the data suggest LMF-HSFx may reduce the insulin resistance in NAFLD patients through the regulation of Adiponectin-AdipoR1/2 pathways [36], which contribute the critical part of insulin resistance.